VistaGen Therapeutics, Inc.
VTGN
$2.22
-$0.12-5.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -47.51% | -11.52% | 28.43% | 50.44% | 49.66% |
| Total Depreciation and Amortization | 10.13% | 9.01% | 6.98% | 6.67% | 5.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -37.82% | -48.70% | -58.08% | -68.61% | 38.12% |
| Change in Net Operating Assets | 726.09% | 178.71% | 135.52% | -71.32% | -153.93% |
| Cash from Operations | -49.16% | -7.02% | 30.35% | 47.65% | 54.52% |
| Capital Expenditure | -311.56% | -1,209.60% | -178.32% | 71.37% | 84.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,347.09% | -2,363.22% | -878.53% | 91.80% | -164.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.08% | 100.12% | 30.88% | 4.84% | -79.78% |
| Issuance of Common Stock | -99.03% | 1,180,363.64% | 843,088.31% | 77,372.84% | 67,698.85% |
| Repurchase of Common Stock | -33,660.00% | -33,660.00% | -33,660.00% | -33,660.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -200.23% | -211.97% | 100.00% | 5.80% |
| Cash from Financing | -99.15% | 172.64% | 79,743.12% | 12,454.87% | 20,810.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -151.07% | 1,909.32% | 320.23% | 299.10% | 273.06% |